Microbiome-Targeted Therapies as an Adjunct to Traditional Weight Loss Interventions: A Systematic Review and Meta-Analysis

Abstract

Tina Peckmezian,1 Vanessa Garcia-Larsen,2 Kayla Wilkins,3 Rana H Mosli,4 Nasser F BinDhim,5– 7 George Kunnackal John,8 Muhammad Yasir,9,10 Esam Ibraheem Azhar,9,10 Gerard E Mullin,11 Saleh A Alqahtani11,12 1Independent Scholar, Sydney, NSW, Australia; 2Program in Human Nutrition, Department of International Health, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; 3Environmental GeoScience Research Group, Trent University, Peterborough, ON, Canada; 4Clinical Nutrition Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia; 5Sharik Association for Health Research, Riyadh, Saudi Arabia; 6College of Medicine, Alfaisal University, Riyadh, Saudi Arabia; 7Saudi Food and Drug Authority, Riyadh, Saudi Arabia; 8Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Easton, MD, USA; 9Special Infectious Agents Unit – BSL3, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia; 10Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia; 11Liver Transplant Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia; 12Division of Gastroenterology & Hepatology, John Hopkins University, Baltimore, MD, USACorrespondence: Saleh A Alqahtani, Liver Transplant Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia, Email [email protected]: This study evaluated the effect of microbiome-targeted therapies (pre-, pro-, and synbiotics) on weight loss and other anthropometric outcomes when delivered as an adjunct to traditional weight loss interventions in overweight and obese adults.Methods: A systematic review of three databases (Medline [PubMed], Embase, and the Cochrane Central Register of Controlled Trials) was performed to identify randomized controlled trials published between January 1, 2010 and December 31, 2020, that evaluated anthropometric outcomes following microbiome-targeted supplements in combination with dietary or dietary and exercise interventions. The pooled mean difference (MD) between treatment and control groups was calculated using a random effects model.Results: Twenty-one trials with 1233 adult participants (76.4% female) with overweight or obesity were included. Separate meta-analyses were conducted for probiotics (n=11 trials) and synbiotics (n=10 trials) on each anthropometric outcome; prebiotics were excluded as only a single study was found. Patient characteristics and methodologies varied widely between studies. All studies incorporated some degree of caloric restriction, while only six studies included recommendations for adjunct exercise. Compared with dietary or dietary and exercise interventions only, probiotics resulted in reductions in body weight (MD: − 0.73 kg; 95% confidence interval [CI]: − 1.02 to − 0.44, p < 0.001), fat mass (MD: − 0.61 kg; 95% CI: − 0.77 to − 0.45; p< 0.001) and waist circumference (MD: − 0.53 cm; 95% CI: − 0.99 to − 0.07, p=0.024) while synbiotics resulted in reductions in fat mass (MD: − 1.53 kg; 95% CI: − 2.95 to − 0.12, p=0.034) and waist circumference (MD: − 1.31 cm; 95% CI: − 2.05 to − 0.57, p< 0.001).Conclusion: This analysis indicates that microbiome-targeted supplements may enhance weight loss and other obesity outcomes in adults when delivered as an adjunct to dietary or dietary and exercise interventions. Personalized therapy to include microbiome-targeted supplements may help to optimize weight loss in overweight and obese individuals.Keywords: microbiome, obesity, adjunctive therapy, weight loss

Keywords

• microbiome
• obesity
• adjunctive therapy
• weight loss